A clinical study on the screening efficacy of six thrombotic markers TAT, PIC, TM, t-PAI-C, D-D, and FDP for hypercoagulable state in pregnant women.

Objective: To investigate the screening efficacy of six thrombotic markers for hypercoagulable state (HCS) in pregnant women, including thrombin-antithrombin III complex (TAT), plasmin-alpha-2 plasmin inhibitor complex (PIC), thrombomodulin (TM), tissue-type plasminogen activator inhibitor complex(t-PAI-C), D-dimer(D-D), and fibrinogen degradation products (FDP).

Methods: This was a retrospective study. Eighty-five high-risk pregnant women who underwent antenatal examination at Baoding maternal and Child Health Hospital from December 2022 to September 2023 were included as the observation group, while 85 healthy pregnant women without complications or comorbidities who underwent routine antenatal examinations at our hospital were randomly enrolled as the control group. Analyzed the screening value of these six thrombotic markers in pregnant women at risk of HCS.

Results: The levels of TAT, PIC, TM, FDP, and D-D in the observation group were significantly higher than in the control group (P < 0.05, respectively). Pearson correlation analysis showed a weak correlation between maternal age and TAT levels (r = -0.179, P< 0.05) as well as between BMI and FDP and D-D (r = 0.214, 0.232, P< 0.05, respectively). Binary logistic regression analysis revealed that abnormal D-D levels were a risk factor for HCS in pregnant women (OR = 0.117, 95% CI: 0.621-0.639, P< 0.05). The area under the joint curve was 0.757, indicating that the model is of certain predictive value for HCS in pregnant women.

Conclusion: TAT, PIC, TM, t-PAI-C, D-D, and FDP can used for the screening of HCS in pregnant women and have a certain predictive value for high-risk pregnant women.